Development of a validated RP-LC/ESI-MS-MS method for separation, identification and determination of related substances of tamsulosin in bulk drugs and formulations

Journal of Pharmaceutical and Biomedical Analysis

Volumn 46, Issue 1, 2008, Pages 94-103

  Nageswara Rao, R ^a   Kumar Talluri, M V N ^a   Narasa Raju, A ^a   Shinde, Dhananjay D ^a   Ramanjaneyulu, G S ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Benign prostatic hyperplasia (BPH); Bulk drugs and formulations; ESI MS MS; Process related impurities; RP HPLC; Tamsulosin

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; TAMSULOSIN;

ACCURACY; ARTICLE; DIODE; DRUG DETERMINATION; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG IMPURITY; DRUG PURITY; DRUG SCREENING; ELECTROSPRAY MASS SPECTROMETRY; ELUTION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG INDUSTRY; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFONAMIDES; TANDEM MASS SPECTROMETRY; TEMPERATURE;

EID: 36749062911     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2007.09.009     Document Type: Article

References (23)

1. Rigatti P. Eur. Urol. 5 Suppl (2006) 989-990
2. In: Sweetman S.C. (Ed). Martindale, The Complete Drug Reference. 33rd ed. (2002), Pharmaceutical Press, London 655
3. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 9th ed., Section V, CD ROM, McGraw-Hill, 1996.
4. Narayan P., and Tewari A. J. Urol. 160 (1998) 1701-1706
5. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Invest. Group Urol. 51 (1998) 892-900
6. Dunn C.J., Matheson A., and Faulds D.M. Drugs Aging 19 (2002) 135-161
7. Chapple C., and Andersson K.E. World J. Urol. 19 (2002) 397-404
8. Aboul-Enein H.Y., Hussein R.F., Radwan M.A., Yusuf A., Al-Ahmadi W., and Al- Rawithi S. J. Liq. Chromatogr. Relat. Technol. 26 (2003) 1109-1116
9. Özkan S.A., Uslu B., and Aboul-Enein H.Y. Talanta 61 (2003) 147-156
10. Matsushima H., Takanuki K., Kamimura H., Watanabe T., and Higuchi S. J. Chromatogr. B 695 (1997) 317-327
11. Ding L., Li L., Tao P., Yang J., and Zhang Z. J. Chromatogr. B 767 (2002) 75-81
12. Ramakrishna N.V.S., Vishwottam K.N., Manoj S., Koteshwara M., Wishu S., and Varma D.P. Biomed. Chromatogr. 19 (2005) 709-719
13. Qi M., Wang P., and Liu L. J. Chromatogr. B 805 (2004) 7-11
14. Soeishi Y., Kobori M., Kobayashi S.I., and Higuchi S. J. Chromatogr. B 533 (1990) 291-296
15. Macek J., Klíma J., and Ptáček P. J. Chromatogr. B 809 (2004) 307-311
16. Keski-Rahkonen P., Pärssinen O., Leppänen E., Mauriala T., Lehtonen M., and Auriola S. J. Pharm. Biomed. Anal. 17 (2007) 606-612
17. Zhang Z., Yang G., Liang G., Liu H., and Chen Y. J. Pharm. Biomed. Anal. 34 (2004) 689-693
18. Kavalírová A., Pospíšilová M., and Karlícek R. Farmaco 60 (2005) 834-839
19. Maier V., Horakova J., Petr J., Tesarova E., Coufal P., and Sevcik J. J. Pharm. Biomed. Anal. 39 (2005) 691-696
20. Petr J., Maier V., Horáková J., and Sevcík J. Electrophoresis 27 (2006) 4735-4745
21. Zhang Y.P., Zhang Y.J., Gong W.J., Wang S.M., Xue H.Y., and Lee K.P. J. Liq. Chromatogr. Relat. Technol. 30 (2007) 215-234
22. ICH International conference on harmonization of technical requirements for registration of Pharmaceuticals for Human use, Impurities in New Drug 22 Products, Geneva, Switzerland 2002, Q3A (R1).
23. ICH International conference on harmonization of technical requirements for registration of Pharmaceuticals for Human use, Impurities in New Drug 25 Products, Geneva, Switzerland 2003, Q3B (R1).